Health Care & Life Sciences » Biotechnology | Alder BioPharmaceuticals Inc.

Alder BioPharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
23,227.00
55,872.00
305,172.00
351,867.00
276,240.00
412,369
Total Accounts Receivable
316.00
113.00
-
-
-
-
Inventories
-
-
-
936.00
-
-
Other Current Assets
1,982.00
4,758.00
17,029.00
40,380.00
11,014.00
7,440
Total Current Assets
25,525.00
60,743.00
322,201.00
393,183.00
287,254.00
419,809
Net Property, Plant & Equipment
1,214.00
1,160.00
1,974.00
7,076.00
5,630.00
6,400
Total Investments and Advances
-
-
75,840.00
865.00
10,222.00
-
Other Assets
-
2,456.00
12.00
8,030.00
30.00
30
Total Assets
26,739.00
64,359.00
400,027.00
409,154.00
303,136.00
426,239
Accounts Payable
2,223.00
1,911.00
4,727.00
10,361.00
7,471.00
Other Current Liabilities
20,845.00
3,098.00
7,645.00
15,529.00
15,895.00
Total Current Liabilities
23,068.00
5,009.00
12,372.00
25,890.00
23,366.00
Other Liabilities
35,659.00
193.00
138.00
481.00
495.00
Total Liabilities
58,727.00
5,202.00
12,510.00
26,371.00
23,861.00
Common Equity (Total)
143,362.00
59,157.00
387,517.00
382,783.00
279,275.00
Total Shareholders' Equity
31,988.00
59,157.00
387,517.00
382,783.00
279,275.00
Total Equity
31,988.00
59,157.00
387,517.00
382,783.00
279,275.00
Liabilities & Shareholders' Equity
26,739.00
64,359.00
400,027.00
409,154.00
303,136.00
Preferred Stock (Carrying Value)
111,374.00
-
-
-
-

About Alder BioPharmaceuticals

View Profile
Address
11804 North Creek Parkway South
Bothell Washington 98011
United States
Employees -
Website http://www.alderbio.com
Updated 07/08/2019
Alder Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6.